3SBio Inc.

Equities

1530

KYG8875G1029

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:20 2024-04-26 am EDT 5-day change 1st Jan Change
6.08 HKD +0.50% Intraday chart for 3SBio Inc. +9.35% -19.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
3Sbio Inc. Announces Management Changes CI
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia MT
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication CI
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023. CI
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates MT
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024 CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product MT
Mandi Foam of 3SBio Inc. Approves for Market Launch CI
Venus Medtech Names Former 3SBio Finance Chief as CFO MT
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China MT
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates MT
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
3SBio Hires Former JPMorgan Exec as CFO MT
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer CI
3SBio Rolls Out Pruritus Medication in China MT
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market CI
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired. CI
3SBio Enrolls First Patient in Phase 3 Trial of Thrombocytopenia Treatment MT
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 11 July 2023 CI
3SBio Inc. Announces First Patient Enrolled in the Trial of Phase III Clinical Study of Recombinant Human Thrombopoietin Injection CI
3Sbio Inc. Announces That the First Patient Recently Been Enrolled in the Trial of Phase Iii Clinical Study of Recombinant Human Thrombopoietin Injection CI
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on July 11, 2023 CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Allorion Therapeutics announced that it has received $50 million in funding from a group of investors CI
Chart 3SBio Inc.
More charts
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
5.599 CNY
Average target price
6.887 CNY
Spread / Average Target
+23.00%
Consensus
  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. News 3SBio Inc.
  5. 3SBio Shareholders to Vote for Off-Market Buyback Proposal